Neuroscience 2005 Abstract
| Presentation Number: | 1035.12 |
|---|---|
| Abstract Title: | Feasibility of sensitive measures of adiposity and insulin resistance in children with psychiatric disorders. |
| Authors: |
Flavin, K. S.*1
; Haupt, D.1
; Hessler, M. J.1
; Fahnestock, P.1
; Schweiger, J. A.1
; Newcomer, J. W.1
1Dept Psych (Box 8134), Washington Univ. School of Medicine, St. Louis, MO |
| Primary Theme and Topics |
Disorders of the Nervous System - Behavioral Pharmacology -- Other |
| Session: |
1035. Behavioral Pharmacology II Poster |
| Presentation Time: | Wednesday, November 16, 2005 4:00 PM-5:00 PM |
| Location: | Washington Convention Center - Hall A-C, Board # WW34 |
| Keywords: | Pediatrics, Antipsychotics, Metabolic Disturbances |
The prevalence of overweight and obesity, insulin resistance, hyperglycemia, dyslipidemia and type 2 diabetes mellitus (T2DM) are increasing in children, with epidemic rates reported in children in the United States. Increased adiposity and related reductions in insulin sensitivity are major risk factors for the development of hyperglycemia, dyslipidemia, and cardiovascular disease. Antipsychotic medications are extensively used in children, with certain agents producing greater increases in weight and adiposity than other commonly used drugs in this age group. However, no study in children has sensitively quantified the metabolic effects of widely used atypical antipsychotics. Adiposity can be directly measured using whole-body glucose and lipid kinetics measured with stable isotope tracer methodology during hyperinsulinemic-euglycemic clamp conditions, whole body dual energy x-ray absorptiometry (DEXA), and abdominal magnetic resonance imaging (MRI). These sensitive methods can be used to measure tissue-specific changes in insulin sensitivity that might occur independent or dependent on fat mass. This ongoing pilot study addresses the feasibility of these metabolic measures in children aged 7-17 with aggressive symptoms related to various psychiatric conditions. Children can be demonstrated to readily tolerate measurement of a) glucose and lipid kinetics with stable isotope tracers, b) area-under-the-curve for post-load insulin and c-peptide during frequently sampled oral glucose tolerance tests, c) body composition with DEXA and MRI, and d) indirect calorimetry. Relevant data are critically needed to target clinical therapy and basic research, identify medical risks, and guide regulatory decisions in this vulnerable population.
Supported by Sydney R. Baer Foundation, MH63985 and Washington University General Clinical Research Center USPHS MO1 RR00036, Washington University Clinical Nutrition Research Center Grant P30 DK56341 and P60-DK20579
<B>Conflict of Interest:</B> No significant financial conflict of interest as defined by the Washington University School of Medicine Conflict of Interest Policy. Other Grant Support: NIMH, Sidney R. Baer Foundation, Janssen Pharmaceutia, Eli Lilly and Co
Sample Citation:
[Authors]. [Abstract Title]. Program No. XXX.XX. 2005 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2005. Online.
Copyright © 2005-2025 Society for Neuroscience; all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.
